Thus, the preliminary available data suggest that tumour HLA-G expression as a single parameter is not associated with poor clinical outcome of cervical carcinoma patients, only in combination with HLA-class I downregulation [22,23]. This evidence concerns the gene HLA-G and neoplasm.